These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38066880)

  • 21. Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program.
    Levy GG; Asikanius E; Kuebler P; Benchikh El Fegoun S; Esbjerg S; Seremetis S
    J Thromb Haemost; 2019 Sep; 17(9):1470-1477. PubMed ID: 31124272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A.
    Le Quellec S
    Drug Des Devel Ther; 2020; 14():469-481. PubMed ID: 32099331
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Should emicizumab be used in patients with acquired hemophilia A?
    Tiede A; Kemkes-Matthes B; Knöbl P
    J Thromb Haemost; 2021 Mar; 19(3):637-644. PubMed ID: 33306259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prophylaxis for hemophilia A without inhibitors: treatment options and considerations.
    Valentino LA; Khair K
    Expert Rev Hematol; 2020 Jul; 13(7):731-743. PubMed ID: 32573295
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET.
    Castaman G; Santoro C; Coppola A; Mancuso ME; Santoro RC; Bernardini S; Pugliese FR; Lubrano R; Golato M; Tripodi A; Rocino A; Santagostino E; ; Biasoli C; Borchiellini A; Catalano A; Contino L; Coluccia A; Cultrera D; De Cristofaro R; Di Minno G; Fabbri A; Franchini M; Gamba G; Giuffrida AC; Gresele P; Giampaolo A; Hassan HJ; Luciani M; Marchesini E; Marino R; Mazzucconi MG; Molinari AC; Morfini M; Notarangelo LD; Peccarisi L; Peyvandi F; Pollio B; Rivolta GF; Ruggieri MP; Sargentini V; Schiavoni M; Sciacovelli L; Serino ML; Siragusa S; Tagliaferri A; Testa S; Tosetto A; Zampogna S; Zanon E
    Blood Transfus; 2020 Mar; 18(2):143-151. PubMed ID: 31657709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Emicizumab, a bispecific antibody mimicking factor VIII: a novel alternative therapy for hemophilia A with inhibitors].
    Nogami K
    Rinsho Ketsueki; 2019; 60(5):475-479. PubMed ID: 31168016
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of switching prophylaxis treatment from factor VIII to emicizumab in hemophilia A patients without inhibitors.
    Escobar M; Agrawal N; Chatterjee S; Bhattacharya S; Caicedo J; Bullano M; Schultz BG
    J Med Econ; 2023; 26(1):574-580. PubMed ID: 36989380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A real-world study comparing pre-post billed annualized bleed rates and total cost of care among non-inhibitor patients with hemophilia A switching from FVIII prophylaxis to emicizumab.
    Batt K; Schultz BG; Caicedo J; Hollenbeak CS; Agrawal N; Chatterjee S; Bullano M
    Curr Med Res Opin; 2022 Oct; 38(10):1685-1693. PubMed ID: 35880468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thrombin generation for monitoring hemostatic therapy in hemophilia A: A narrative review.
    Verhagen MJA; Valke LLFG; Schols SEM
    J Thromb Haemost; 2022 Apr; 20(4):794-805. PubMed ID: 35034413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis.
    Astermark J; Buckner TW; Frenzel L; Hatswell AJ; You X; Liu H; Goodman E; Santos S; Hawes C; Hinds D; Klamroth R
    Haemophilia; 2023 Jul; 29(4):1087-1094. PubMed ID: 37347645
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hemorrhagic and thrombotic adverse events associated with emicizumab and extended half-life factor VIII replacement drugs: EudraVigilance data of 2021.
    Abbattista M; Ciavarella A; Noone D; Peyvandi F
    J Thromb Haemost; 2023 Mar; 21(3):546-552. PubMed ID: 36710195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A.
    Gelbenegger G; Schoergenhofer C; Knoebl P; Jilma B
    Thromb Haemost; 2020 Oct; 120(10):1357-1370. PubMed ID: 32717759
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X.
    Ogiwara K; Nogami K; Matsumoto N; Noguchi-Sasaki M; Hirata M; Soeda T; Shima M
    Int J Hematol; 2020 Nov; 112(5):621-630. PubMed ID: 32748217
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial.
    Reyes A; Révil C; Niggli M; Chebon S; Schlagmüller S; Flacke JP; Zortel M; Paz-Priel I; Asikanius E; Hampton R; Mahajan A; Schmidt E; Edwards SC
    Curr Med Res Opin; 2019 Dec; 35(12):2079-2087. PubMed ID: 31355677
    [No Abstract]   [Full Text] [Related]  

  • 35. A hemophilia A mouse model for the in vivo assessment of emicizumab function.
    Ferrière S; Peyron I; Christophe OD; Kawecki C; Casari C; Muczynski V; Nathwani A; Kauskot A; Lenting PJ; Denis CV
    Blood; 2020 Aug; 136(6):740-748. PubMed ID: 32369559
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emicizumab in acquired hemophilia A: pros and cons of a new approach to the prevention and treatment of bleeding.
    Pasca S; Zanon E; Mannucci PM; Peyvandi F
    Blood Transfus; 2023 Nov; 21(6):549-556. PubMed ID: 36795341
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute treatment of intracranial hemorrhage complicated by hemophilia a and emicizumab therapy.
    Clark K; Patrick BM; Torian SC
    Am J Emerg Med; 2024 Feb; 76():272.e1-272.e2. PubMed ID: 38123423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emicizumab Use in Treatment of Acquired Hemophilia A: A Case Report.
    Al-Banaa K; Alhillan A; Hawa F; Mahmood R; Zaki A; El Abdallah M; Zimmerman J; Musa F
    Am J Case Rep; 2019 Jul; 20():1046-1048. PubMed ID: 31318850
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Channeling effects in the prescription of new therapies: the case of emicizumab for hemophilia A.
    Mahajerin A; Faghmous I; Kuebler P; Howard M; Xu T; Flores C; Chang T; Nissen F
    J Comp Eff Res; 2022 Jul; 11(10):717-728. PubMed ID: 35535702
    [No Abstract]   [Full Text] [Related]  

  • 40. Expert opinion paper on the treatment of hemophilia a with emicizumab.
    López-Jaime FJ; Benítez O; Díaz Jordán BL; Montaño A; Coll J; Quintana París L; Gómez-Del Castillo Solano MDC
    Hematology; 2023 Dec; 28(1):2166334. PubMed ID: 36636993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.